Saturday, November 23, 2024
11/23/2024
Abstract Ultra-high dose rate (UHDR) radiation delivery, termed FLASH radiotherapy (FLASH-RT), has the potential to reduce normal tissue damage, with significant clinical cancer treatment ramifications. Current evidence suggests that FLASH-RT reduces functional damage to normal brain, colon, lung, and skin, at the same dose values. Although controversial, some studies show this reduction in tissue damage as great as 40%, despite tissue type alpha/beta ratio and total dose remain significant unknown factors. Most surprisingly tumor tissue appears unaffected by FLASH radiation sparing, suggesting that the therapeutic ratio achieved through FLASH-RT is higher than conventional RT. The potential to achieve higher therapeutic ratios make FLASH-RT very attractive for future human use to address radioresistant tumors that would otherwise result in excessive radiotoxicity during conventional treatment. Despite clinical translation of FLASH-RT to large animal and human studies being urgently warranted, the majority of the preclinical work for FLASH-RT remains in small animals, where concerns regarding dose and dose rate inhomogeneities cannot be adequately assessed. A major barrier towards translational FLASH-RT is that optimization of treatment plans for large animals and humans with larger/deeper tissues and complicated geometries remains challenging. In order to demonstrate the hypothesized superiority of FLASH-RT, it is essential to conduct the studies FLASH-RT studies under controlled conditions and in clinically realistic workflows. This begins with a treatment planning system {TPS) capable of generating and delivering comparable plans for FLASH/CONV-RT within a minimally modified clinical setting. In the current proposal, we are committed to developing such a TPS for the first time and making our software available to the scientific community. We will achieve this by first generating beam models for FLASH-capable linacs. These beam models will then be used to implement advanced planning and delivery technology utilizing passive intensity modulation. Next, we will develop tumor control probability and normal tissue complication probability models deployable on the TPS. Lastly, our work will culminate in demonstrating successful deliveries of optimized plans with comprehensive characterization of plan delivery using quality assurance systems uniquely available at Dartmouth. Due to the urgency to transfer this paradigm-shifting therapy, high-risk of the first initiative, the exploratory, and developmental nature of the proposal, the R21 grant mechanism is leveraged and justified. The successful completion of the proposed work will advance the state-of-the-art in FLASH-RT by bridging the extensive gap between the basic science of FLASH and the clinical needs of FLASH for translation to human trials. The team has leading expertise in radiation physics, informatics, and radiation oncology, and are supported by existing FLASH-capable linacs, TPS prototypes, unique UHDR dosimetry technologies invented at Dartmouth, canine pilot trials, future human trials in planning and leading industrial partners. Taken together, the team is ideally poised to conduct the proposed work of exploratory and developmental nature.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
